E
BIO icon

Ergoteles’s Bio-Rad Laboratories Class A BIO Stock Holding History

Ergoteles’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,039
Closed -$773K – 124
2023
Q2 		$773K Sell
2,039
-2,002
-50% -$815K 0.04% 530
2023
Q1 		$1.94M Sell
4,041
-4,728
-54% -$2.21M 0.08% 282
2022
Q4 		$3.69M Buy
8,769
+7,388
+535% +$2.98M 0.14% 153
2022
Q3 		$576K Buy
+1,381
New +$689K 0.02% 702
2021
Q1 		– Sell
-1,300
Closed -$758K – 810
2020
Q4 		$758K Buy
+1,300
New +$740K 0.03% 380

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ergoteles's BIO Position: Q3 2023 in Review

Ergoteles sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2023, closing a stake of 2,039 shares — an estimated $773K sold.

Ergoteles first reported a position in BIO in Q4 2020 and held it in 5 quarters. The position peaked at $3.69M in Q4 2022. 467 funds tracked by Wall St. Rank hold BIO as of Q3 2023.

  • Ergoteles reported no remaining Bio-Rad Laboratories Class A position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 2,039 Bio-Rad Laboratories Class A shares in Q3 2023, an estimated $773K.
  • Ergoteles first reported a position in Bio-Rad Laboratories Class A in Q4 2020 and held it in 5 quarters.
  • Ergoteles's Bio-Rad Laboratories Class A position peaked at $3.69M in Q4 2022.
  • 467 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.